Abstract
The results of the phase 2 trial of pyrotinib plus capecitabine for patients with brain metastases arising from HER2-positive breast cancer are welcome news—breast cancer brain metastases are both common and feared. 1 Yan M Ouyang Q Sun T et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022; 23: 353-361 Summary Full Text Full Text PDF PubMed Scopus (12) Google Scholar New CNS-active systemic therapies will benefit many patients. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trialTo our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population. This combination deserves further validation in a randomised, controlled trial. Full-Text PDF Screening for breast cancer brain metastases – Authors' replyWe thank Jonathan Knisely for his response to our Article on the PERMEATE study of brain metastases in breast cancer. We agree that current guidelines need to be updated to recommend regular screening for brain metastases, especially for asymptomatic patients with HER2-positive or triple-negative metastatic breast cancer. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
